Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M846Revenue $M75.4Net Margin (%)-100.2Z-Score-0.8
Enterprise Value $M818EPS $-0.5Operating Margin %-94.8F-Score4
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-100.1Higher ROA y-yN
Price/Book29.310-y EBITDA Growth Rate %-13.1Quick Ratio2.0Cash flow > EarningsY
Price/Sales8.55-y EBITDA Growth Rate %16.4Current Ratio2.0Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-99.2Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-408.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M160ROI % (ttm)-84.5Gross Margin Increase y-yY

Gurus Latest Trades with AVNR

Number of guru portfolios checked: 56.

No Entry found!

AVNR is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


AVNR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Siffert Joao MDSVP, R&D 2014-05-28Sell13,547$5.184.05 view
Katkin KeithPresident and CEO 2014-05-28Sell442,212$5.017.58 view
OCAMPO CHRISTINEVice President, Finance 2014-05-16Sell37,496$5.056.73 view
Katkin KeithPresident and CEO 2013-12-18Sell29,515$2.67101.87 view
OCAMPO CHRISTINEVice President, Finance 2013-12-18Sell2,450$2.63104.94 view
Siffert Joao MDSVP, R&D 2013-12-18Sell5,970$2.63104.94 view
PALEKAR ROHANSVP & Chief Commercial Officer 2013-12-17Buy10,000$2.892.5 view
PALEKAR ROHANSVP & Chief Commercial Officer 2013-11-04Buy10,000$4.1928.64 view
Katkin KeithPresident and CEO 2013-11-01Sell4,385$4.1430.19 view
Siffert Joao MDSVP, R&D 2013-09-18Sell21,094$4.2227.73 view

Press Releases about AVNR :

    Quarterly/Annual Reports about AVNR:

    News about AVNR:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
    Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
    Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
    Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
    Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
    Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
    Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 
    Avanir Pharmaceuticals Reports Operating Results (10-Q) Aug 05 2010 
    Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 105,906 Shares May 04 2010 

    More From Other Websites
    Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study Jul 16 2014
    Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study Jul 16 2014
    3 Biotech Stocks Under $10 to Trade for Breakouts Jul 11 2014
    Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting Jul 09 2014
    Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the... Jun 30 2014
    Avanir Pharmaceuticals Announces Two Data Presentations Related to Pseudobulbar Affect (PBA) at the... Jun 30 2014
    Avanir to present data related to safety and efficacy of AVP-825 Jun 24 2014
    Avanir Pharmaceuticals Announces Three Data Presentations Related to AVP-825 for the Acute Treatment... Jun 24 2014
    Avanir Gains - AVP-825 Hits Phase III Primary Endpoint Jun 12 2014
    Avanir Pharmaceuticals Announces Positive Outcome of Phase IIIb COMPASS Trial: A Head-to-Head Study... Jun 10 2014
    Patients Enrolled in Avanir Study Jun 02 2014
    Pipeline Update from Avanir Jun 02 2014
    NPS Pharmaceuticals (NPSP) in Focus: Stock Rises 13.4% Jun 02 2014
    Avanir Pharmaceuticals Announces Multiple Data Presentations Related to Pseudobulbar Affect (PBA)... May 30 2014
    Avanir Pharmaceuticals to Participate in Two Conferences in June May 28 2014
    Avanir completes patient enrollment in study of AVP-923 May 27 2014
    Avanir Pharmaceuticals Announces Completion of Patient Enrollment in Study of AVP-923 for the... May 27 2014
    Stock To Watch: AVANIR Pharmaceuticals (AVNR) In Perilous Reversal May 15 2014
    Avanir (AVNR) Shares March Higher, Can It Continue? May 15 2014
    Avanir Pharmaceuticals (AVNR) in Focus: Stock Moves 6.1% Higher May 15 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide